Cargando…

Clinical outcomes of levosimendan versus dobutamine in patients with acute decompensated heart failure with reduced ejection fraction and impaired renal function

To assess the clinical outcomes of levosimendan and dobutamine in patients with acute decompensated heart failure with reduced ejection fraction and impaired renal function in Indian scenario. Cardiac, renal, electrolytes and hepatic parameters as well as the clinical outcomes were assessed. Levosim...

Descripción completa

Detalles Bibliográficos
Autores principales: John, Basil, Babu, Mariya, shaji, Sandramol, Abraham, Suja, Abdullakutty, Jabir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322823/
https://www.ncbi.nlm.nih.gov/pubmed/34154760
http://dx.doi.org/10.1016/j.ihj.2021.02.010
_version_ 1783731137301970944
author John, Basil
Babu, Mariya
shaji, Sandramol
Abraham, Suja
Abdullakutty, Jabir
author_facet John, Basil
Babu, Mariya
shaji, Sandramol
Abraham, Suja
Abdullakutty, Jabir
author_sort John, Basil
collection PubMed
description To assess the clinical outcomes of levosimendan and dobutamine in patients with acute decompensated heart failure with reduced ejection fraction and impaired renal function in Indian scenario. Cardiac, renal, electrolytes and hepatic parameters as well as the clinical outcomes were assessed. Levosimendan and dobutamine improved ejection fraction significantly. Levosimendan in comparison to dobutamine, increased cardiac output (0.76 vs. −0.38 at 48 h, 1.15 vs. −0.31 day 7, -2.02 vs. −1.51 day 30), cardiac index (0.89 vs.-0.13 at 48 h, 1.16 vs. −0.07 at day 7 and 1.05 vs. −0.25 at day 30) and eGFR (−1.4 vs. −0.75 at day 30) significantly. Levosimendan reduced ICU stay (p = 0.038) significantly whereas dobutamine decreased the hospital stay duration (p = 0.015). There was no major difference in re-hospitalization and mortality between groups. Ventricular tachyarrhythmia was the main adverse event noted in Levosimendan arm. Levosimendan showed improved cardiac as well as renal outcomes within a month when compared to dobutamine and it is the first study to determine the renal parameters of Levosimendan in an Indian setting.
format Online
Article
Text
id pubmed-8322823
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-83228232021-07-31 Clinical outcomes of levosimendan versus dobutamine in patients with acute decompensated heart failure with reduced ejection fraction and impaired renal function John, Basil Babu, Mariya shaji, Sandramol Abraham, Suja Abdullakutty, Jabir Indian Heart J Research Brief To assess the clinical outcomes of levosimendan and dobutamine in patients with acute decompensated heart failure with reduced ejection fraction and impaired renal function in Indian scenario. Cardiac, renal, electrolytes and hepatic parameters as well as the clinical outcomes were assessed. Levosimendan and dobutamine improved ejection fraction significantly. Levosimendan in comparison to dobutamine, increased cardiac output (0.76 vs. −0.38 at 48 h, 1.15 vs. −0.31 day 7, -2.02 vs. −1.51 day 30), cardiac index (0.89 vs.-0.13 at 48 h, 1.16 vs. −0.07 at day 7 and 1.05 vs. −0.25 at day 30) and eGFR (−1.4 vs. −0.75 at day 30) significantly. Levosimendan reduced ICU stay (p = 0.038) significantly whereas dobutamine decreased the hospital stay duration (p = 0.015). There was no major difference in re-hospitalization and mortality between groups. Ventricular tachyarrhythmia was the main adverse event noted in Levosimendan arm. Levosimendan showed improved cardiac as well as renal outcomes within a month when compared to dobutamine and it is the first study to determine the renal parameters of Levosimendan in an Indian setting. Elsevier 2021 2021-02-17 /pmc/articles/PMC8322823/ /pubmed/34154760 http://dx.doi.org/10.1016/j.ihj.2021.02.010 Text en © 2021 Cardiological Society of India. Published by Elsevier B.V. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Research Brief
John, Basil
Babu, Mariya
shaji, Sandramol
Abraham, Suja
Abdullakutty, Jabir
Clinical outcomes of levosimendan versus dobutamine in patients with acute decompensated heart failure with reduced ejection fraction and impaired renal function
title Clinical outcomes of levosimendan versus dobutamine in patients with acute decompensated heart failure with reduced ejection fraction and impaired renal function
title_full Clinical outcomes of levosimendan versus dobutamine in patients with acute decompensated heart failure with reduced ejection fraction and impaired renal function
title_fullStr Clinical outcomes of levosimendan versus dobutamine in patients with acute decompensated heart failure with reduced ejection fraction and impaired renal function
title_full_unstemmed Clinical outcomes of levosimendan versus dobutamine in patients with acute decompensated heart failure with reduced ejection fraction and impaired renal function
title_short Clinical outcomes of levosimendan versus dobutamine in patients with acute decompensated heart failure with reduced ejection fraction and impaired renal function
title_sort clinical outcomes of levosimendan versus dobutamine in patients with acute decompensated heart failure with reduced ejection fraction and impaired renal function
topic Research Brief
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322823/
https://www.ncbi.nlm.nih.gov/pubmed/34154760
http://dx.doi.org/10.1016/j.ihj.2021.02.010
work_keys_str_mv AT johnbasil clinicaloutcomesoflevosimendanversusdobutamineinpatientswithacutedecompensatedheartfailurewithreducedejectionfractionandimpairedrenalfunction
AT babumariya clinicaloutcomesoflevosimendanversusdobutamineinpatientswithacutedecompensatedheartfailurewithreducedejectionfractionandimpairedrenalfunction
AT shajisandramol clinicaloutcomesoflevosimendanversusdobutamineinpatientswithacutedecompensatedheartfailurewithreducedejectionfractionandimpairedrenalfunction
AT abrahamsuja clinicaloutcomesoflevosimendanversusdobutamineinpatientswithacutedecompensatedheartfailurewithreducedejectionfractionandimpairedrenalfunction
AT abdullakuttyjabir clinicaloutcomesoflevosimendanversusdobutamineinpatientswithacutedecompensatedheartfailurewithreducedejectionfractionandimpairedrenalfunction